Content about Ipilimumab

October 17, 2012
Bristol-Myers Squibb skin cancer drug wins Prix Galien USA Prize

A cancer drug made by Bristol-Myers Squibb has received an award from Galien Foundation, the drug maker said Wednesday.

PRINCETON, N.J. — A cancer drug made by Bristol-Myers Squibb has received an award from Galien Foundation, the drug maker said Wednesday.

The company said Yervoy (ipilimumab) received the 2012 Prix Galien USA Prize in the Best Biotechnology Product category. Yervoy — used to treat melanoma that has spread to other parts of the body, known as metastasis — is the first new drug for melanoma that is metastatic or can't be removed through surgery in more than a decade.

June 2, 2011
BMS, Roche to study skin cancer drugs

Bristol-Myers Squibb will collaborate with Roche to investigate the use of a combination of the companies’ drugs in patients with a deadly form of skin cancer.

NEW YORK — Bristol-Myers Squibb will collaborate with Roche to investigate the use of a combination of the companies’ drugs in patients with a deadly form of skin cancer.

The companies will conduct a phase 1/2 trial to test the safety and efficacy of BMS’ Yervoy (ipilimumab) in combination with Roche’s investigational drug vemurafenib in patients with melanoma that has spread to other parts of the body.

March 25, 2011
FDA approves Bristol's cancer drug

The Food and Drug Administration has approved a new treatment for late-stage skin cancer, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for late-stage skin cancer, the agency said Friday.

The FDA approved Bristol-Myers Squibb’s Yervoy (ipilimumab) for patients with melanoma that has spread to other parts of the body, also known as metastasis. More than 68,000 new cases of melanoma were diagnosed in the United States in 2010, and about 8,700 died from it, according to the National Cancer Institute, part of the National Institutes of Health.

March 24, 2011
Bristol: Ipilimumab boosts survival rates among patients in phase-3 trial

Bristol-Myers Squibb said its late-stage clinical trial for a cancer treatment, which currently is under review by the Food and Drug Administration, achieved its primary endpoint.

PRINCETON, N.J. — Bristol-Myers Squibb said its late-stage clinical trial for a cancer treatment, which currently is under review by the Food and Drug Administration, achieved its primary endpoint.

The company said its phase-3 trial for investigational compound ipilimumab, designed for previously untreated patients that were diagnosed with metastatic melanoma, improved overall survival. The study compared the combination of ipilimumab 10 mg/kg and chemotherapy (dacarbazine) with chemotherapy alone.

August 17, 2010
FDA grants priority review for Bristol-Myer Squibb's skin cancer treatment

The Food and Drug Administration has agreed to expedite review of an investigational treatment for...

June 21, 2010
Datamonitor: Melanoma cases expected to double

Cases of the potentially deadly skin cancer melanoma are expected to almost double before the...

NEW YORK Cases of the potentially deadly skin cancer melanoma are expected to almost double before the end of the decade, according to a new report by research firm Datamonitor.

 

Research by the company indicated that cases of melanoma could go from the 138,000 new cases expected this year to 227,000 by 2019.

 

 

June 6, 2010
Bristol-Myers Squibb: Skin cancer drug increased patient survival in clinical trial

An investigational drug for skin cancer that had spread to other parts of the body...

January 6, 2010
Pfizer to develop cancer drug with Debiopharm

Two drug makers have entered an agreement to develop a drug designed to treat melanoma....